Tiziana Life Sciences Plc

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.86%68.420.0%$2138.49m
NVAXNovavax, Inc. 7.15%142.8296.5%$1213.63m
SRNESorrento Therapeutics, Inc. -6.15%12.212.8%$753.59m
GILDGilead Sciences, Inc. 0.80%68.731.0%$572.53m
AMGNAmgen, Inc. 0.25%239.451.3%$469.72m
REGNRegeneron Pharmaceuticals, Inc. 0.59%614.492.7%$387.04m
VRTXVertex Pharmaceuticals, Inc. 0.03%267.231.9%$353.27m
BIIBBiogen, Inc. 0.40%289.681.6%$351.48m
ILMNIllumina, Inc. -2.08%346.183.5%$344.45m
BNTXBioNTech SE -2.68%69.100.0%$343.58m
ATNMActinium Pharmaceuticals, Inc. -1.11%9.8013.3%$233.99m
VXRTVaxart, Inc. 0.99%9.180.0%$214.33m
EBSEmergent BioSolutions, Inc. -1.33%133.146.4%$196.75m
MCRBSeres Therapeutics, Inc. -4.51%27.293.6%$178.46m
ALXNAlexion Pharmaceuticals, Inc. 1.29%103.202.0%$165.17m

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.